Arrowhead Pharmaceuticals... (ARWR)
| Bid | 13.87 |
| Market Cap | 1.93B |
| Revenue (ttm) | 2.5M |
| Net Income (ttm) | -639.71M |
| EPS (ttm) | -5.15 |
| PE Ratio (ttm) | -2.73 |
| Forward PE | -3.8 |
| Analyst | Buy |
| Ask | 17.4 |
| Volume | 929,521 |
| Avg. Volume (20D) | 1,791,674.7 |
| Open | 13.89 |
| Previous Close | 13.89 |
| Day's Range | 13.45 - 14.25 |
| 52-Week Range | 9.57 - 30.41 |
| Beta | 1.00 |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P...
Analyst Forecast
According to 10 analyst ratings, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $34.5, which is an increase of 145.29% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · businesswire.com
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial OfficerPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will reti...
2 months ago · seekingalpha.com
Arrowhead Pharmaceuticals: Progress During Adverse Market ConditionsArrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with...
2 months ago · seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical S...